Skip to main content

Table 5 Whole-body bone SPECT/CT detection rates according to pre-test PSA classes

From: Does whole-body bone SPECT/CT provide additional diagnostic information over [18F]-FCH PET/CT for the detection of bone metastases in the setting of prostate cancer biochemical recurrence?

PSA class Bone metastatic patient N (%)
> 10 ng/mL 14/28 (50%)
2–10 ng/mL 11/65 (17%)
1–2 ng/mL 1/12 (8%)
<  1 ng/mL 1/10 (10%)
Total 27/115 (23%)
  1. The numbers and percentages are expressed in relation to the total number of patients in each PSA class